DBVT
DBV Technologies S.A.
NASDAQ · Healthcare · Biotechnology · FR
$13.47
−1.68%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- -49.3%
- EBIT
- -46.2%
- EPS
- +43.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +71.7%
- EPS
- +67.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- -25.5%
- EBIT
- -22.0%
- Net income
- -29.2%
- EPS
- -41.7%
- Free cash flow
- -13.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026